Literature DB >> 6353530

Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children--a multicentered evaluation of dosage and safety.

P F Wright, J D Cherry, H M Foy, W P Glezen, C B Hall, K McIntosh, A S Monto, R H Parrott, B Portnoy, L H Taber.   

Abstract

Clinical trials of monovalent A/USSR/77 (H1N1) and trivalent A/USSR/77 (H1N1), A/Texas/77 (H3N2), and B/Hong Kong/72 inactivated influenza virus vaccines were carried out in 358 children and adolescents. Only split-virus vaccines were administered to children younger than 13 years of age. No serious local or systemic reactions were observed among the study participants. Two doses of vaccine containing 7-20 micrograms of the A/USSR/77 (H1N1) viral antigen were required to achieve serum titers of hemagglutinin-inhibiting (HA1) antibody greater than 1:40. However, single doses containing 7-20 micrograms of the A/Texas/77 (H3N2) or B/Hong Kong/72 antigens stimulated serum HAI antibody levels of 1:40.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6353530     DOI: 10.1093/clinids/5.4.758

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  15 in total

Review 1.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

2.  Immune response to influenza vaccination in children with cancer.

Authors:  Dimitrios Doganis; Athanasia Kafasi; Helen Dana; Nikolaos Spanakis; Margarita Baka; Apostolos Pourtsidis; Triantafyllia Sdogou; Artemis Vintila; Vaia Rafailidou; Panagiota Chantzi; Marina Servitzoglou; Despina Bouhoutsou; Maria Varvoutsi; Helen Kosmidis; Maria Tsolia
Journal:  Hum Vaccin Immunother       Date:  2018-06-08       Impact factor: 3.452

3.  Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).

Authors:  Luzhao Feng; Peng Yang; Tao Zhang; Juan Yang; Chuanxi Fu; Ying Qin; Yi Zhang; Chunna Ma; Zhaoqiu Liu; Quanyi Wang; Genming Zhao; Hongjie Yu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis.

Authors:  U B Schaad; U Bühlmann; R Burger; A Ruedeberg; A Wilder-Smith; M Rutishauser; F Sennhauser; C Herzog; M Zellmeyer; R Glück
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Relative antigenicity in mice of H1N1, H3N2 and B strains present in inactivated influenza virus vaccines.

Authors:  M L Profeta; M Ruggeri
Journal:  Eur J Epidemiol       Date:  1987-03       Impact factor: 8.082

6.  Safety and immunogenicity of a novel quadrivalent subunit influenza vaccine in animal models.

Authors:  Huayue Ye; Siyue Jia; Yuhui Zhang; Jingxin Li; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

7.  Response to influenza immunisation during treatment for cancer.

Authors:  J C Chisholm; T Devine; A Charlett; C R Pinkerton; M Zambon
Journal:  Arch Dis Child       Date:  2001-06       Impact factor: 3.791

8.  Immunogenicity and protection of oral influenza vaccines formulated into microparticles.

Authors:  Prathap Nagaraja Shastri; Min-Chul Kim; Fu-Shi Quan; Martin J D'Souza; Sang-Moo Kang
Journal:  J Pharm Sci       Date:  2012-06-18       Impact factor: 3.534

9.  A novel synthetic receptor-based immunoassay for influenza vaccine quantification.

Authors:  Anwar M Hashem; Caroline Gravel; Aaron Farnsworth; Wei Zou; Michelle Lemieux; Kangwei Xu; Changgui Li; Junzhi Wang; Marie-France Goneau; Maria Merziotis; Runtao He; Michel Gilbert; Xuguang Li
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

Review 10.  New vaccines against influenza virus.

Authors:  Young-Tae Lee; Ki-Hye Kim; Eun-Ju Ko; Yu-Na Lee; Min-Chul Kim; Young-Man Kwon; Yinghua Tang; Min-Kyoung Cho; Youn-Jeong Lee; Sang-Moo Kang
Journal:  Clin Exp Vaccine Res       Date:  2013-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.